ArticleNature communications2025
Small molecule inhibitor targets OmpV to treat pandemic Vibrio cholerae infection.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trait-based signatures associated with persistence and thermal benefit in a genomically decayed coral probiotic.The ISME journal · 2026Article
- Outer membrane vesicles inMicrobial cell (Graz, Austria) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholera, a severe diarrhoeal illness caused by Vibrio cholerae (V. cholerae), poses a significant threat to public health worldwide. The emergence of multidrug-resistant V. cholerae strains underscores the urgent need for preventive and therapeutic interventions. In this study, we elucidate the role of outer membrane protein V (OmpV) in the virulence of V. cholerae and propose a therapeutic strategy targeting OmpV. Subcellular localization analysis shows that OmpV is present in both the bacterial outer membrane (OM) and bacterial extracellular vesicles (BEVs). When V. cholerae enters the small intestine, OmpV is activated by the CarSR two-component system in response to cationic antimicrobial peptides (CAMPs) in the small intestine, leading to increased bacterial pathogenicity. The upregulation of ompV not only augments bacterial adhesion but also promotes the internalization of BEVs into host cells, thereby increasing the delivery of cholera toxin (CT) to host cells. Computational aided drug design (CADD) shows that the small-molecule inhibitor C607-0736 is capable of disrupting the virulence functions of OmpV. Animal experiments show that C607-0736 efficiently inhibits the colonization and pathogenicity of the V. cholerae O1 and O139 strains. These findings underscore the therapeutic potential of OmpV-targeting strategies and offer promising avenues for addressing multidrug-resistant V. cholerae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.